LSK BioPartners Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Salt Lake City UT United States (2005)
Status: Acquired by Elevar Therapeutics (2019)

Organization Overview

First Clinical Trial
2012
NCT01497704
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

LSK BioPartners | LSK BioPartners Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

lapatinib (tykerb) (7 trials)

Drugs in Phase 2 Trials (4)

paclitaxel (taxol) (1 trial)

pembrolizumab (keytruda) (1 trial)

tipiracil (lonsurf) (1 trial)

trifluridine (viroptic) (1 trial)

Drugs in Phase 1 Trials (1)

nivolumab (opdivo) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 3)

Carcinoma, Transitional Cell (Phase 2)

Colorectal Neoplasms (Phase 2)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 2)

Stomach Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 6